On August 4, Artelo Biosciences (NASDAQ ticker: ARTL) announced the completion of a $9.475 million over-the-counter private placement, which will be used to launch a digital asset reserve strategy centered on Solana (SOL), becoming the first listed pharmaceutical company to include SOL in its reserve assets.
This private placement includes the issuance of common stock (or prepaid warrants) at a price of $10.45 per share, as well as two batches of three-year warrants with exercise prices of $10.20 and $50, respectively. The transaction is expected to be completed on August 5, 2025.





